Angelini’s acquisition of Arvelle for $1bn

  • Industry: Biotechnology
  • Deal value: $960mn
  • Deal consideration: All-cash
  • Acquirer advisors: KPMG (due diligence, tax and accounting)
  • Target advisors: Centerview Partners
©Angelini Pharma
  • Headquartered in: Rome, Italy
  • Revenue FY2019: $737.6mn
  • EBITDA FY2019: $148mn
  • EBITDA margin: 20.1%
©Arvelle Therapeutics
  • Headquartered in: Zug, Switzerland
  • Funding raised: $176mn



Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
M&A Hub

M&A Hub


Weekly updates on world’s biggest and most interesting M&A deals.